Brivaracetam to Treat Partial Onset Seizures in Adults
Authors:
- 1 January 2022
- journal article
- research article
- Published by Journal of Biological Methods in Health Psychology Research
- Vol. 10 (5) , 56782
Abstract
Purpose of Review: Seizures are a hyperexcitable, and hypersynchronous imbalance between excitatory and inhibitory factors (E/I imbalance) in neurotransmission, and epilepsy is the recurrent manifestation of seizures within a reasonable time frame and without being attributable to a reversible cause. Brivaracetam is a derivative of the antiepileptic agent, levetiracetam, that is used as adjuvant therapy for focal onset seizures. It was approved by the FDA in 2016 and has shown promising results with minimal adverse effect reactions in clinical trials. Recent Findings: Brivaracetam has been used in multiple clinical trials at various dosages in adults that have partial-onset seizures refractory to conventional treatment. A meta-analysis in 2016 showed that brivaracetam as adjunctive therapy was statically significant in its reduction of adults with drug-refractory seizure frequency.1 The most commonly reported adverse effects that patients who were taking brivaracetam experienced were somnolence, headache, and dizziness. Further studies are necessary to conclude long term efficacy and safety profile of brivaracetam. Conclusion: The treatment of epilepsy with pharmacologic agents is a difficult task due to balancing the efficacy of the drug with the side effect profile that will allow for the best quality of life for the patient. There are approximately 30 antiepileptic agents for clinicians to choose from. Brivaracetam is a novel antiepileptic agent that was approved for use by the FDA in 2016 and is showing promising results as monotherapy and adjunctive therapy in individuals with drug-refractory focal seizures while minimizing adverse drug reactions.Keywords
This publication has 50 references indexed in Scilit:
- Synchronization and desynchronization in epilepsy: controversies and hypothesesThe Journal of Physiology, 2013
- Vagus nerve stimulation for epilepsy: A review of the peripheral mechanismsSurgical Neurology International, 2012
- Changes in action potential features during focal seizure discharges in the entorhinal cortex of the in vitro isolated guinea pig brainJournal of Neurophysiology, 2011
- Targeting SV2A for discovery of antiepileptic drugsEpilepsia, 2010
- The postictal state: Effects of age and underlying brain dysfunctionEpilepsy & Behavior, 2010
- Adjunctive brivaracetam for refractory partial-onset seizuresNeurology, 2010
- Reevaluating the mechanisms of focal ictogenesis: The role of low‐voltage fast activityEpilepsia, 2009
- The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy menBritish Journal of Clinical Pharmacology, 2008
- How Long Do Most Seizures Last? A Systematic Comparison of Seizures Recorded in the Epilepsy Monitoring UnitEpilepsia, 2006
- The Prognosis for Seizure Control in Newly Diagnosed EpilepsyNew England Journal of Medicine, 1984